New York, Jan 23, 2026, 11:42 EST — Regular session
Rocket Lab Corp shares climbed 3.1% to $90.72 by 11:31 a.m. EST on Friday, bouncing between $86.13 and $91.96 earlier in the session. The stock had closed Thursday at $87.98 after falling as low as $81.35, still trading under its 52-week peak of $99.58. The Nasdaq was up roughly 0.5% in late morning action.
The rebound shifts attention to Neutron, Rocket Lab’s upcoming rocket and the program investors see as a move from small-satellite launches to larger missions. Any delay in its maiden flight wouldn’t just push back a date — it could alter short-term expectations for bookings, cash flow, and the pace of Rocket Lab’s growth.
Rocket Lab reported this week that during qualification testing, Neutron’s Stage 1 tank ruptured in a hydrostatic pressure trial— a test designed to push the tank’s structural limits. According to an SEC filing and a company statement, there was no major damage to facilities. The firm is now analyzing test data to determine any effect on its launch timeline.
TD Cowen analyst Gautam Khanna flagged that the tank problem might delay the planned first flight. He noted in a Jan. 21 investor note, referenced by Aviation Week, that a launch delay caused by the tank rupture would likely rule out a second Neutron launch in 2026.
Rocket Lab touted operational gains, completing its first Electron launch of 2026 by sending two satellites for Open Cosmos into a 1,050-km circular orbit from New Zealand. Founder and CEO Sir Peter Beck described the mission as “a great showcase” for dedicated Electron flights, highlighting “accurate constellation deployment” and “streamlined access to space.” The company also said another Electron launch is coming soon. GlobeNewswire
Space.com noted that the Electron mission released the satellites roughly 70 minutes post-liftoff, marking Rocket Lab’s 80th flight. This follows their record-setting pace of 21 launches in 2025.
According to a separate SEC filing, director Jon A. Olson offloaded 15,205 Rocket Lab shares on Jan. 20 as part of a Rule 10b5-1 plan established in September 2025. After these transactions, he still holds 345,630 shares.
The Neutron test failure hits a stock that’s already surged and is priced more on execution risk than actual revenue. If the review calls for a redesign instead of chalking it up to a one-off test failure, the timeline could stretch out. Investors don’t usually have much patience when development programs start to slip.
The company’s fourth-quarter earnings call in February is next on the calendar, where Rocket Lab intends to provide an update on the Neutron schedule. This will be a key early indicator of whether Friday’s bounce-back can stick.
